vs
Side-by-side financial comparison of Akebia Therapeutics, Inc. (AKBA) and RIGEL PHARMACEUTICALS INC (RIGL). Click either name above to swap in a different company.
RIGEL PHARMACEUTICALS INC is the larger business by last-quarter revenue ($69.8M vs $57.6M, roughly 1.2× Akebia Therapeutics, Inc.). On growth, Akebia Therapeutics, Inc. posted the faster year-over-year revenue change (23.9% vs 21.2%). Over the past eight quarters, RIGEL PHARMACEUTICALS INC's revenue compounded faster (53.7% CAGR vs 32.9%).
Akebia Therapeutics is a biopharmaceutical company dedicated to developing and commercializing novel therapies for patients with kidney diseases, particularly anemia linked to chronic kidney disease. It operates across global markets, focusing on addressing unmet medical needs in the nephrology care segment.
Rigel Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing targeted small molecule therapies for autoimmune, inflammatory, and hematologic diseases. Its approved flagship product treats adult immune thrombocytopenia, with primary operations and core markets in the United States, addressing unmet medical needs for underserved patient groups.
AKBA vs RIGL — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $57.6M | $69.8M |
| Net Profit | — | $268.1M |
| Gross Margin | 78.2% | 91.5% |
| Operating Margin | -14.8% | 33.2% |
| Net Margin | — | 384.0% |
| Revenue YoY | 23.9% | 21.2% |
| Net Profit YoY | — | 1769.2% |
| EPS (diluted) | $-0.05 | $14.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $57.6M | $69.8M | ||
| Q3 25 | $58.8M | $69.5M | ||
| Q2 25 | $62.5M | $101.7M | ||
| Q1 25 | $57.3M | $53.3M | ||
| Q4 24 | $46.5M | $57.6M | ||
| Q3 24 | $37.4M | $55.3M | ||
| Q2 24 | $43.6M | $36.8M | ||
| Q1 24 | $32.6M | $29.5M |
| Q4 25 | — | $268.1M | ||
| Q3 25 | $540.0K | $27.9M | ||
| Q2 25 | $247.0K | $59.6M | ||
| Q1 25 | $6.1M | $11.4M | ||
| Q4 24 | — | $14.3M | ||
| Q3 24 | $-20.0M | $12.4M | ||
| Q2 24 | $-8.6M | $-1.0M | ||
| Q1 24 | $-18.0M | $-8.2M |
| Q4 25 | 78.2% | 91.5% | ||
| Q3 25 | 84.0% | 93.2% | ||
| Q2 25 | 84.1% | 95.6% | ||
| Q1 25 | 86.7% | 91.7% | ||
| Q4 24 | 56.2% | 89.9% | ||
| Q3 24 | 62.2% | 85.5% | ||
| Q2 24 | 60.9% | 92.4% | ||
| Q1 24 | 64.4% | 93.1% |
| Q4 25 | -14.8% | 33.2% | ||
| Q3 25 | 7.6% | 40.9% | ||
| Q2 25 | 22.6% | 60.1% | ||
| Q1 25 | 23.6% | 23.9% | ||
| Q4 24 | -30.8% | 28.9% | ||
| Q3 24 | -33.4% | 25.4% | ||
| Q2 24 | -20.0% | 1.2% | ||
| Q1 24 | -45.8% | -23.6% |
| Q4 25 | — | 384.0% | ||
| Q3 25 | 0.9% | 40.2% | ||
| Q2 25 | 0.4% | 58.6% | ||
| Q1 25 | 10.7% | 21.5% | ||
| Q4 24 | — | 24.9% | ||
| Q3 24 | -53.5% | 22.5% | ||
| Q2 24 | -19.7% | -2.8% | ||
| Q1 24 | -55.2% | -27.9% |
| Q4 25 | $-0.05 | $14.11 | ||
| Q3 25 | $0.00 | $1.46 | ||
| Q2 25 | $0.00 | $3.28 | ||
| Q1 25 | $0.03 | $0.63 | ||
| Q4 24 | $-0.10 | $0.82 | ||
| Q3 24 | $-0.10 | $0.70 | ||
| Q2 24 | $-0.04 | $-0.06 | ||
| Q1 24 | $-0.09 | $-0.47 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $184.8M | $155.0M |
| Total DebtLower is stronger | $48.3M | $52.5M |
| Stockholders' EquityBook value | $32.6M | $391.5M |
| Total Assets | $376.6M | $513.6M |
| Debt / EquityLower = less leverage | 1.48× | 0.13× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $184.8M | $155.0M | ||
| Q3 25 | $166.4M | $137.1M | ||
| Q2 25 | $137.3M | $108.4M | ||
| Q1 25 | $113.4M | $77.1M | ||
| Q4 24 | $51.9M | $77.3M | ||
| Q3 24 | $34.0M | $61.1M | ||
| Q2 24 | $39.5M | $49.1M | ||
| Q1 24 | $42.0M | $49.5M |
| Q4 25 | $48.3M | $52.5M | ||
| Q3 25 | $47.6M | $60.0M | ||
| Q2 25 | $47.1M | $60.0M | ||
| Q1 25 | $46.5M | $60.0M | ||
| Q4 24 | $38.7M | $60.0M | ||
| Q3 24 | $38.4M | $60.0M | ||
| Q2 24 | $38.0M | $60.0M | ||
| Q1 24 | $30.1M | $60.0M |
| Q4 25 | $32.6M | $391.5M | ||
| Q3 25 | $41.6M | $117.6M | ||
| Q2 25 | $29.2M | $81.9M | ||
| Q1 25 | $24.6M | $18.6M | ||
| Q4 24 | $-49.2M | $3.3M | ||
| Q3 24 | $-50.4M | $-14.6M | ||
| Q2 24 | $-33.8M | $-29.9M | ||
| Q1 24 | $-27.3M | $-31.7M |
| Q4 25 | $376.6M | $513.6M | ||
| Q3 25 | $364.2M | $242.5M | ||
| Q2 25 | $345.6M | $206.7M | ||
| Q1 25 | $310.2M | $176.0M | ||
| Q4 24 | $220.7M | $164.0M | ||
| Q3 24 | $207.1M | $139.4M | ||
| Q2 24 | $220.2M | $128.4M | ||
| Q1 24 | $225.5M | $126.5M |
| Q4 25 | 1.48× | 0.13× | ||
| Q3 25 | 1.15× | 0.51× | ||
| Q2 25 | 1.61× | 0.73× | ||
| Q1 25 | 1.89× | 3.23× | ||
| Q4 24 | — | 18.25× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $31.1M | $22.0M |
| Free Cash FlowOCF − Capex | $31.1M | — |
| FCF MarginFCF / Revenue | 53.9% | — |
| Capex IntensityCapex / Revenue | 0.1% | — |
| Cash ConversionOCF / Net Profit | — | 0.08× |
| TTM Free Cash FlowTrailing 4 quarters | $67.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $31.1M | $22.0M | ||
| Q3 25 | $28.1M | $24.0M | ||
| Q2 25 | $22.3M | $30.5M | ||
| Q1 25 | $-13.6M | $-893.0K | ||
| Q4 24 | $-4.5M | $14.5M | ||
| Q3 24 | $-6.7M | $21.7M | ||
| Q2 24 | $-10.1M | $302.0K | ||
| Q1 24 | $-19.4M | $-5.0M |
| Q4 25 | $31.1M | — | ||
| Q3 25 | $28.0M | — | ||
| Q2 25 | $22.2M | — | ||
| Q1 25 | $-13.6M | — | ||
| Q4 24 | $-4.5M | — | ||
| Q3 24 | $-6.7M | — | ||
| Q2 24 | $-10.1M | — | ||
| Q1 24 | — | — |
| Q4 25 | 53.9% | — | ||
| Q3 25 | 47.7% | — | ||
| Q2 25 | 35.6% | — | ||
| Q1 25 | -23.7% | — | ||
| Q4 24 | -9.6% | — | ||
| Q3 24 | -17.9% | — | ||
| Q2 24 | -23.1% | — | ||
| Q1 24 | — | — |
| Q4 25 | 0.1% | — | ||
| Q3 25 | 0.1% | — | ||
| Q2 25 | 0.2% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.1% | — | ||
| Q1 24 | 0.0% | — |
| Q4 25 | — | 0.08× | ||
| Q3 25 | 52.05× | 0.86× | ||
| Q2 25 | 90.47× | 0.51× | ||
| Q1 25 | -2.22× | -0.08× | ||
| Q4 24 | — | 1.01× | ||
| Q3 24 | — | 1.75× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AKBA
| Auryxia | $48.1M | 84% |
| Vafseo | $6.2M | 11% |
| License Collaboration And Other Revenue | $3.3M | 6% |
RIGL
Segment breakdown not available.
